Funding and services needed to achieve universal health coverage: applications of global, regional, and national estimates of utilisation of outpatient visits and inpatient admissions from 1990 to 2016, and unit costs from 1995 to 2016.


Journal

The Lancet. Public health
ISSN: 2468-2667
Titre abrégé: Lancet Public Health
Pays: England
ID NLM: 101699003

Informations de publication

Date de publication:
01 2019
Historique:
received: 16 08 2018
accepted: 18 10 2018
pubmed: 16 12 2018
medline: 6 5 2020
entrez: 16 12 2018
Statut: ppublish

Résumé

To inform plans to achieve universal health coverage (UHC), we estimated utilisation and unit cost of outpatient visits and inpatient admissions, did a decomposition analysis of utilisation, and estimated additional services and funds needed to meet a UHC standard for utilisation. We collated 1175 country-years of outpatient data on utilisation from 130 countries and 2068 country-years of inpatient data from 128 countries. We did meta-regression analyses of annual visits and admissions per capita by sex, age, location, and year with DisMod-MR, a Bayesian meta-regression tool. We decomposed changes in total number of services from 1990 to 2016. We used data from 795 National Health Accounts to estimate shares of outpatient and inpatient services in total health expenditure by location and year and estimated unit costs as expenditure divided by utilisation. We identified standards of utilisation per disability-adjusted life-year and estimated additional services and funds needed. In 2016, the global age-standardised outpatient utilisation rate was 5·42 visits (95% uncertainty interval [UI] 4·88-5·99) per capita and the inpatient utilisation rate was 0·10 admissions (0·09-0·11) per capita. Globally, 39·35 billion (95% UI 35·38-43·58) visits and 0·71 billion (0·65-0·77) admissions were provided in 2016. Of the 58·65% increase in visits since 1990, population growth accounted for 42·95%, population ageing for 8·09%, and higher utilisation rates for 7·63%; results for the 67·96% increase in admissions were 44·33% from population growth, 9·99% from population ageing, and 13·55% from increases in utilisation rates. 2016 unit cost estimates (in 2017 international dollars [I$]) ranged from I$2 to I$478 for visits and from I$87 to I$22 543 for admissions. The annual cost of 8·20 billion (6·24-9·95) additional visits and 0·28 billion (0·25-0·30) admissions in low-income and lower-middle income countries in 2016 was I$503·12 billion (404·35-605·98) or US$158·10 billion (126·58-189·67). UHC plans can be based on utilisation and unit costs of current health systems and guided by standards of utilisation of outpatient visits and inpatient admissions that achieve the highest coverage of personal health services at the lowest cost. Bill & Melinda Gates Foundation.

Sections du résumé

BACKGROUND
To inform plans to achieve universal health coverage (UHC), we estimated utilisation and unit cost of outpatient visits and inpatient admissions, did a decomposition analysis of utilisation, and estimated additional services and funds needed to meet a UHC standard for utilisation.
METHODS
We collated 1175 country-years of outpatient data on utilisation from 130 countries and 2068 country-years of inpatient data from 128 countries. We did meta-regression analyses of annual visits and admissions per capita by sex, age, location, and year with DisMod-MR, a Bayesian meta-regression tool. We decomposed changes in total number of services from 1990 to 2016. We used data from 795 National Health Accounts to estimate shares of outpatient and inpatient services in total health expenditure by location and year and estimated unit costs as expenditure divided by utilisation. We identified standards of utilisation per disability-adjusted life-year and estimated additional services and funds needed.
FINDINGS
In 2016, the global age-standardised outpatient utilisation rate was 5·42 visits (95% uncertainty interval [UI] 4·88-5·99) per capita and the inpatient utilisation rate was 0·10 admissions (0·09-0·11) per capita. Globally, 39·35 billion (95% UI 35·38-43·58) visits and 0·71 billion (0·65-0·77) admissions were provided in 2016. Of the 58·65% increase in visits since 1990, population growth accounted for 42·95%, population ageing for 8·09%, and higher utilisation rates for 7·63%; results for the 67·96% increase in admissions were 44·33% from population growth, 9·99% from population ageing, and 13·55% from increases in utilisation rates. 2016 unit cost estimates (in 2017 international dollars [I$]) ranged from I$2 to I$478 for visits and from I$87 to I$22 543 for admissions. The annual cost of 8·20 billion (6·24-9·95) additional visits and 0·28 billion (0·25-0·30) admissions in low-income and lower-middle income countries in 2016 was I$503·12 billion (404·35-605·98) or US$158·10 billion (126·58-189·67).
INTERPRETATION
UHC plans can be based on utilisation and unit costs of current health systems and guided by standards of utilisation of outpatient visits and inpatient admissions that achieve the highest coverage of personal health services at the lowest cost.
FUNDING
Bill & Melinda Gates Foundation.

Identifiants

pubmed: 30551974
pii: S2468-2667(18)30213-5
doi: 10.1016/S2468-2667(18)30213-5
pmc: PMC6323358
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e49-e73

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Références

Health Policy. 2002 Jul;61(1):1-19
pubmed: 12173493
Int J Technol Assess Health Care. 2003 Spring;19(2):396-406
pubmed: 12862196
Trop Med Int Health. 2012 Jan;17(1):23-35
pubmed: 22008480
Eur J Health Econ. 2015 Jan;16(1):21-33
pubmed: 24337894
N Engl J Med. 2015 Apr 2;372(14):1281-5
pubmed: 25830419
Lancet. 2015 Aug 29;386(9996):928-30
pubmed: 26138141
PLoS Med. 2015 Aug 04;12(8):e1001860
pubmed: 26241895
N Engl J Med. 2015 Oct;373(14):1285-9
pubmed: 26422719
Nature. 2015 Dec 3;528(7580):S53-9
pubmed: 26633766
BMC Med. 2016 Jul 20;14(1):108
pubmed: 27439621
JAMA. 2016 Dec 27;316(24):2627-2646
pubmed: 28027366
Health Policy Plan. 2017 Mar 1;32(2):267-276
pubmed: 28207049
Epidemiol Serv Saude. 2017 Jan-Mar;26(1):215-222
pubmed: 28226024
Lancet Glob Health. 2017 Sep;5(9):e875-e887
pubmed: 28728918
Lancet. 2017 Sep 16;390(10100):1423-1459
pubmed: 28916366
Lancet. 2017 Sep 16;390(10100):1084-1150
pubmed: 28919115
Lancet. 2017 Sep 16;390(10100):1211-1259
pubmed: 28919117
Lancet. 2017 Nov 18;390(10109):2230
pubmed: 29165260
Lancet. 2018 Mar 17;391(10125):1108-1120
pubmed: 29179954
Lancet Glob Health. 2018 Feb;6(2):e152-e168
pubmed: 29248365
Lancet. 2018 Mar 24;391(10126):1205-1223
pubmed: 29397200
Cost Eff Resour Alloc. 2018 Mar 19;16:11
pubmed: 29559855
Lancet. 2018 May 5;391(10132):1783-1798
pubmed: 29678341
Lancet. 2018 May 5;391(10132):1799-1829
pubmed: 29678342
Lancet. 2018 Jun 2;391(10136):2236-2271
pubmed: 29893224
Lancet. 2018 Nov 10;392(10159):2052-2090
pubmed: 30340847

Auteurs

Mark W Moses (MW)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Paola Pedroza (P)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Ranju Baral (R)

PATH, Seattle, WA, USA.

Sabina Bloom (S)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Jonathan Brown (J)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Abby Chapin (A)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Kelly Compton (K)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Erika Eldrenkamp (E)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Nancy Fullman (N)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

John Everett Mumford (JE)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Vishnu Nandakumar (V)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Katherine Rosettie (K)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Nafis Sadat (N)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Tom Shonka (T)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Abraham Flaxman (A)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Theo Vos (T)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Chris J L Murray (CJL)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Marcia R Weaver (MR)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA. Electronic address: mweaver@uw.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH